Pasithea Therapeutics (KTTA) EBITDA (2021 - 2024)
Historic EBITDA for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$3.1 million.
- Pasithea Therapeutics' EBITDA rose 3757.27% to -$3.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.9 million, marking a year-over-year increase of 1289.36%. This contributed to the annual value of -$13.9 million for FY2024, which is 1289.36% up from last year.
- Pasithea Therapeutics' EBITDA amounted to -$3.1 million in Q4 2024, which was up 3757.27% from -$3.0 million recorded in Q3 2024.
- In the past 5 years, Pasithea Therapeutics' EBITDA registered a high of $623344.0 during Q4 2021, and its lowest value of -$5.0 million during Q4 2023.
- In the last 4 years, Pasithea Therapeutics' EBITDA had a median value of -$3.3 million in 2023 and averaged -$2.9 million.
- Its EBITDA has fluctuated over the past 5 years, first plummeted by 89759.75% in 2022, then soared by 3757.27% in 2024.
- Over the past 4 years, Pasithea Therapeutics' EBITDA (Quarter) stood at $623344.0 in 2021, then crashed by 897.6% to -$5.0 million in 2022, then decreased by 1.47% to -$5.0 million in 2023, then surged by 37.57% to -$3.1 million in 2024.
- Its last three reported values are -$3.1 million in Q4 2024, -$3.0 million for Q3 2024, and -$3.9 million during Q2 2024.